The FDA grants "breakthrough" status to blood-cancer treatment ibrutinib, which is being...

|By:, SA News Editor

The FDA grants "breakthrough" status to blood-cancer treatment ibrutinib, which is being developed by Pharmacyclics (PCYC +3.7%) and J&J (JNJ), for two rare types of lymphoma. The designation was created last year and could enable drug approval after just an expanded early stage study. The companies  now plan to file for authorization of Ibrutinib by the end of the year. (PR)